Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
210.60 SEK | -1.03% |
|
-1.63% | +9.37% |
05-28 | Oxcap Analytics Starts Epiroc at Equalweight | MT |
05-28 | Stockholm Bullets - Elekta up on report, Irlab climbs on positive study results | FW |
Summary: Epiroc AB
- The company has a good ESG score relative to its sector, according to MSCI.
Highlights: Epiroc AB
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses: Epiroc AB
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company benefits from high valuations in earnings multiples.
- The company's enterprise value to sales, at 4.19 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings Chart: Epiroc AB
Source: Surperformance
ESG chart: Epiroc AB
Source: MSCI
Fundamentals (Composite) | Global Valuation (Composite) | Financial estimates revisions (Composite) | Capi.($) | ||
---|---|---|---|---|---|
25.9B | |||||
47.82B | |||||
34.17B | |||||
34.17B | |||||
28.4B | |||||
15.93B | |||||
15.64B | |||||
12.58B | |||||
10.46B | |||||
Average | 25.01B | ||||
Weighted average by Cap. |
Investor (Composite)
Trader (Composite)
ESG MSCI
AA
Financials
Revenue growth
EPS growth
Capital Efficiency (Composite)
Net Margin
Financial Health (Composite)
Valuation
P/E
EV/Revenue
EV/EBITDA
PBR
Dividend Yield
Revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
Revenue revisions (1 month)
EPS revisions (1 year)
EPS revisions (4 months)
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (4 months)
Analysts' target price evolution (1 year)
Business Predictability
Surprise rates
Analysts' coverage
Analysts' recommendations divergence
Analysts' Target price divergence
Financial estimates divergence
ESG
Environment
Social
Governance
Controversy
Ethical controversies
Human rights controversies
Tax subsidies controversies
Sharia compliant
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- EPI A Stock
- Ratings Epiroc AB
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition